CMPS (COMPASS Pathways PLC) Net earnings per one share for the last twelve months

COMPASS Pathways PLC (CMPS) - corporate logo

The price trajectory for COMPASS Pathways plc (CMPS) shown below on the GURU.Markets platform reflects the EPS TTM dynamics, which currently stands at 15.80. This is supported by the pristine condition of laboratory facilities and a strict equipment maintenance protocol. The business focuses on developing psilocybin therapy for clinics, relying on insurance reimbursements, while outsourcing the development of new compounds to external contractors to keep formula ownership in-house.

compasspathways.com (CMPS) Net earnings per share (EPS TTM): for the period 02/11/2024 - 11/10/2026

Compass Pathways - analytical breakdowns and key metrics (CMPS)

- market price and analyst price targets:
Market Chart compasspathways.com|CMPS - Consensus Target
- business market valuation indicators:
Market Value COMPASS Pathways PLC|CMPS - Enterprise Value
- company book value details:
Accounting Value per Share COMPASS Pathways|CMPS - Book Capitalization|Market Value to Book Value compasspathways.com|CMPS - Aggregate Company Assets
- company total debt and liquidity indicators:
Debt to Capital COMPASS Pathways plc|CMPS - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio COMPASS Corp|CMPS - Company Debts|Debts to Book Value COMPASS Pathways PLC|CMPS - Company Long-Term Debt|Company Current Liabilities COMPASS Pathways|Critical Liquidity Ratio compasspathways.com
- earnings and market multiples details:
CMPS - Net Profit|Projected Future Earnings COMPASS Pathways plc|CMPS - Price to Earnings Ratio|Market Cap to Projected Earnings COMPASS Pathways PLC|CMPS - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio COMPASS Pathways PLC|CMPS - Operating profit before deduction of amortization|Earnings per share for the trailing year COMPASS Pathways|CMPS - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months compasspathways.com|CMPS - Earnings growth in current year|Earnings growth forecast for next year COMPASS Pathways plc
Initial company analysis:CMPS, compasspathways.com
Core merchandise of COMPASS Pathways plc

COMPASS Pathways plc (CMPS) operational successes in ethical psychopharmacotherapy are reflected in the annual shift of EPS TTM. This indicator continuously compares the total earnings per share over the last 12 months with the same period last year. Such price action reveals hidden profitability trends by neutralizing quarterly volatility. It is critical for investors to assess this pace as a marker for the effective implementation of the company's ESG strategy and bioethical standards.

Competitor analysis

Net earnings per share for the last four quarters alkermes.com ALKS|AVDL (Avadel Pharmaceuticals plc) - Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months atai Life Sciences NV (ATAI)|GHRS (GH Research Corp) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Mind Medicine Corp (MNMD)|Net earnings per share (EPS TTM) LBRX|DRUG (brightmindsbio.com) - Earnings per share for the trailing year|Earnings per share for the last twelve months Vanda Pharmaceuticals Inc. VNDA|Cybin Inc (CYBN) - Net earnings per one share for the last twelve months|Alto Neuro - Net earnings per share (EPS TTM)|NRx Pharmaceuticals, Inc (NRXP) - Net earnings per share for the last 12 months|cingulate.com (CING) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months silopharma.com (SILO)|Earnings per share for the last twelve months China Pharma Holdings Inc.|Net earnings per share for the last 12 months Clearmind Medicine, Inc. (CMND)|Earnings per share for the last twelve months Psyence Biomedical Limited (PBM)|SPRC: Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) SEEL (Seelos Therapeutics)|Net earnings per share (EPS TTM) Virpax Pharmaceuticals Inc. VRPX|KRTX - Earnings per share for the last twelve months